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Abstract 
Background: In Niger, malaria transmission is markedly seasonal with most of the disease burden occurring in 
children during the rainy season. Seasonal malaria chemoprevention (SMC) with amodiaquine plus sulfadoxine–
pyrimethamine (AQ + SP) is recommended in the country to be administered monthly just before and during the 
rainy season. Moreover, clinical decisions on use of SP for intermittent preventive treatment in pregnancy (IPTp) 
now depend upon the validated molecular markers for SP resistance in Plasmodium falciparum observed in the local 
parasite population. However, little is known about molecular markers of resistance for either SP or AQ in the south 
of Niger. To address this question, clinical samples which met clinical and biological criteria, were collected in Gabi, 
Madarounfa district, Maradi region, Niger in 2011–2012 (before SMC implementation). Molecular markers of resistance 
to pyrimethamine (pfdhfr), sulfadoxine (pfdhps) and amodiaquine (pfmdr1) were assessed by DNA sequencing.
Results: Prior to SMC implementation, the samples showed a high proportion of clinical samples that carried the pfd-
hfr 51I/59R/108N haplotype associated with resistance to pyrimethamine and pfdhps 436A/F/H and 437G mutations 
associated with reduced susceptibility to sulfadoxine. In contrast mutations in codons 581G, and 613S in the pfdhps 
gene, and in pfmdr1, 86Y, 184Y, 1042D and 1246Y associated with resistance to amodiaquine, were less frequently 
observed. Importantly, pfdhfr I164L and pfdhps K540E mutations shown to be the most clinically relevant markers for 
high level clinical resistance to SP were not detected in Gabi.
Conclusions: Although parasites with genotypes associated with the highest levels of resistance to AQ + SP are not 
yet common in this setting, their importance for deployment of SMC and IPTp dictates that monitoring of these mark‑
ers of resistance should accompany these interventions. This study also highlights the parasite heterogeneity within a 
small spatial area and the need to use caution when extrapolating results from surveys of molecular markers of resist‑
ance in a single site to inform regional policy decisions.
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Background
Although there has been great progress in malaria con-
trol, fewer than half of endemic countries account for 85% 
of all reported cases and most of these are in Africa [1]. In 
Niger, according to official estimates, the total number of 
confirmed and presumptive malaria cases was 846,509 in 
2012 which roughly corresponds to a malaria incidence 
rate of 263 per thousand and malaria-related mortality 
was 0.12% [2]. While the entire population is exposed to 
the risk of malaria, the most vulnerable groups are preg-
nant women and children under the age of 5 years [3, 4]. 
Niger is within the Sahel, where malaria is markedly sea-
sonal and most disease occurs during the rainy season 
from June to September. The epidemiological situation in 
Niger is thus suitable for the implementation of seasonal 
malaria chemoprevention (SMC) in children. This treat-
ment involves the monthly administration of sulfadox-
ine–pyrimethamine (SP) and amodiaquine (AQ) during 
the season of high transmission when malaria endemic-
ity and mortality are the highest [4]. Several studies have 
shown that SMC provides protection against malaria, 
resulting in a decrease in the number of clinical episodes 
and mortality, and in the incidence of severe malaria, but 
logistical challenges are formidable in some parts of eligi-
ble regions [5–8].
Malaria episodes during pregnancy compromise the 
health of the mother and the development of her fetus, 
particularly in primiparous women [9]. The World Health 
Organization (WHO) recommends that in high trans-
mission areas, SP be given at least a month apart at the 
4 antenatal visits after the first trimester for preventive 
treatment of malaria (IPTp) [10]. In many regions, clinical 
responses to SP are seriously compromised, and SP is no 
longer recommended for treatment of malaria episodes. 
However, it has been difficult to determine whether the 
efficacy of SP for IPTp is similarly compromised.
These uncertainties mean that decisions about whether 
to introduce SMC or IPTp as additional malaria preven-
tive strategies are partly dependent on the local level of 
resistance to the antimalarial drugs being used [9–11]. 
Epidemiological monitoring of susceptibility to SP can 
be estimated by measuring the prevalence in the para-
site population of key mutations that serve as surrogate 
molecular markers of the clinical response to anti-malar-
ials. For SP, the prevalence of parasites that carry the 
“quintuple mutant” genotype, both the triple mutant hap-
lotype, pfdhfr allele N51I/C59R/S108 N and the double 
mutant haplotype, A437G and K540E mutations of the 
pfdhps gene are strongly associated with clinical failure 
of SP treatment [10, 11]. Similarly, parasites that carry a 
N86Y/F184Y/D1246Y haplotype of the pfmdr1 gene are 
associated with reduced susceptibility to amodiaquine 
[12–15]. Whether SP for IPTp or SP +  AQ for SMC is 
still protective in locations where these genotypes are 
common is under active investigation. Therefore, surveil-
lance of these and other additional markers of SP and AQ 
response is a crucial element of future clinical decisions 
on implementation of SMC and IPTp in Niger.
Information on resistance to anti-malarials is scarce in 
Niger, but an evaluation of these markers of SP and AQ 
resistance can provide a baseline with which to assess any 
changes in these molecular markers associated with the 
implementation of SMC. To that end, this study reports 
the prevalence of mutations of the pfdhfr, pfdhps and 
pfmdr1 genes associated with resistance to SP and AQ 
in Plasmodium falciparum blood samples collected from 
children living in a semi-urban area of Niger before and 
during the implementation of SMC.
Methods
Study site
The study was conducted in at the Gabi community 
health centre, Madarounfa district, Maradi Region along 
the southern border of Niger (Fig.  1). The rainy season 
extends from June to September with an annual average 
(2000–2012) precipitation of 445 mm. A previous study 
showed that the Maradi Region is meso-to hyperendemic 
for malaria with a rate of slide-positivity for inpatients 
peaking at 70% during the season of high transmission 
and falling to 20% during the dry season when the trans-
mission rate is the lowest [16].
Sample collection
Samples for molecular analysis were collected from 
young children presenting at the Gabi health centre. 
After clinical examination, children presenting with fever 
(axillary temperature ≥ 37.5  °C) or history of fever dur-
ing the previous 24 h were tested for malaria. The pres-
ence of P. falciparum was initially investigated by a rapid 
diagnostic test (HRP2 SD  Bioline®) then confirmed and 
quantified by microscopy on Giemsa-stained blood 
smears. Children with uncomplicated P. falciparum 
infection with parasite density between 2000 and 200,000 
per microlitre, aged 6–59 months and/or height greater 
than 65 cm, and weighing more than 5 kg, were identified 
and their parents or caregivers invited to participate in 
the study. Exclusion criteria were the presence of mixed 
infections with species other than P. falciparum or pres-
ence of severe malaria or general danger signs; these chil-
dren were immediately referred for inpatient evaluation. 
The recruitment period extended from December 2011 
to January 2012. After obtaining informed consent from 
parents or guardians, 1 ml of venous blood was collected 
in EDTA anticoagulant tubes. Parasitized blood samples 
were stored frozen at – 20 °C until analysis.
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Ethical considerations
This study was authorized by the Ministry of Health 
of Niger, and ethical clearance was obtained from the 
National Ethical Committee of Niger (authorization 
N°022/2011/CCNE and N°003/2013/CCNE). Documents 
relating to the consent procedure were translated into 
Hausa which is the formal local language. The informa-
tion sheet detailing the purpose of the study was read in 
its entirety to the parents or guardians, and a copy of the 
document was provided. An interview was given to every 
participant and to parents after which the consent form 
was signed, or validated by a fingerprint for illiterate per-
sons. All subjects testing positive for malaria, included 
or not in the study, were treated without charge accord-
ing national protocols. Data from this study have been 
deposited in the WorldWide Antimalarial Resistance 
Network repository for open use in individual patient 
data meta-analyses.
DNA extraction and PCR
Genomic DNA was extracted according to manufactur-
er’s recommendations (QIAamp DNA blood kit, QIA-
GEN). Measurement of the concentration and purity 
of DNA was achieved using a NanoDrop2000 UV-Vis 
spectrophotometer. All amplifications were done in 
a microtube format, using a Primus 96 thermocycler 
(PEQLAB Biotechnology). To analyse parasite popula-
tions that were as homogeneous as possible, clinical 
samples were first typed by amplification of polymor-
phic block 2 sequences of pfmsp2 essentially as described 
elsewhere [15]. Those producing a single fragment by 
agarose gel electrophoresis were judged to be monoclo-
nal and selected for analysis of markers associated with 
resistance. pfdhfr and pfdhps sequences were ampli-
fied by nested PCR as described elsewhere [16]. Briefly, 
M1 (5′TTT ATG ATG GAA CAA GTC TGC3′) and M7 
(5′CTA GTA TAT ACA TCG CTA ACA3′) oligonucleotides 
were used for primary amplification of pfdhfr sequences 
(650  bp) and M3b (5′TGA TGG AAC AAG TCT GCG 
ACGTT3′) and M9 (5′CTG GAA AAA ATA CAT CAC 
A TTC ATA TG3′) for secondary reactions, producing 
a 594  bp fragment containing key mutations A16V/S, 
N51I, C59R, S108N, V140L and I164L. For Pfdhps 
sequences a 770 bp fragment was first amplified using N1 
(5′GAT TCT TTT TCA GAT GGA GG3′) and N2 (5′TTC 
CTC ATG TAA TTC ATC TG A3′) then used as template 
for secondary amplifications using primers R2 (5′AAC 
CTA AAC GTG CTG TTC AA3′) and R (5′AAT TGT GTGA 
TTT GTC CACAA3′). The final PCR product (711  bp) 
contains mutations S436A/F, A437G, K540E, A581G, and 
A613S, previously associated with parasite responses to 
sulfonamide. Detailed PCR conditions for amplification 
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Fig. 1 Map showing the location of the Maradi region in Niger and the location of the capitol, Maradi city where the Gabi Health Centre is located
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of these markers are as described elsewhere [17]. Prim-
ers for cycle-sequencing included; Pfdhps_Fwd (AAC 
CTA AAC GTG CTG TTC AA), Pfdhps_Rev (AAT TGT 
GTG ATT TGT CCA CAA), Pfdhps_IntFwd1 (ATT CTA 
TAG TGT AGT TCT AATGC), Pfdhps_IntRev2 (CTG GAT 
TAT TTG TAC AAG CAC), Pfdhfr_Fwd (TGA TGG AAC 
AAG TCT GCG ACGTT), Pfdhfr_Rev (CTG GAA AAA 
ATA CAT CAC ATT CAT ATG). Cycle sequencing follow 
standard BigDye3.1 dye terminator protocol (AppliedBi-
osystems) on an MJ-Thermocylcer. Sequencing reactions 
were cleaned on Sephadex G10 columns and analysed on 
ABI3130xl Genetic Analyser.
Data analysis
The enrolment period was 1  month, in order to col-
lect approximately 150 blood samples. This sample size 
allows reliable assessment of a prevalence of 12% (corre-
sponding to the prevalence of parasites that carried the 
triple pfdhdr mutation previously observed in Niger [16]) 
with a precision of ±  7%. Data were double-entered by 
two independent entry clerks into EPIinfo version 3.5.2 
(Odensk, Denmark). General characteristics of the popu-
lation were described by mean, standard deviation and 
range for continuous variables and by absolute number 
and percentage for categorical variables.
Results
A total of 201 blood samples were collected and pro-
cessed for DNA amplification. The mean age and the 
mean body weight (and standard deviation) of the 
patients included in the study were 22.8 ± 11.7 months 
[range: 6–55] and 9.5 ± 5.7 kg [range: 5.3–15.5], respec-
tively, with a sex ratio of 1.04 in favour of girls. Patients 
included in the study had a P. falciparum monoinfec-
tion with a median parasite density 14,076 parasites/
mm [range 80–202,000]). Of the 201 samples amplified 
by PCR with pfdhfr, pfdhps and pfmdr1 primers, 120 
(59.7%), 103 (51.2%), and 95 (47.2%), respectively, pro-
duced fragments in sufficient yield for sequencing. The 
electropherograms showed that 13.8, 11.1 and 10.8% 
of the amplified pfdhfr, pfdhps, and pfmdr1 sequences, 
respectively, were heterogeneous consisting of a mixture 
of wild type and mutated residues at one or more indi-
vidual polymorphic positions. These polyclonal clinical 
samples were not included for the calculation of the allele 
prevalence and reconstruction of the various haplotypes. 
In total, 136 amplicons of pfdhps and 120 amplicons of 
pfdhfr were sequenced. Combined genotypes were estab-
lished using the samples that were successfully ana-
lysed at one (pfdhfr, pfdhps or pfmdr1), two (pfdhfr and 
pfdhps), or three (pfdhfr, pfdhps and pfmdr1) loci.
Prevalence of individual point mutations in pfdhfr, pfdhps 
and pfmdr1 genes
Prevalence of individual mutant codons was determined 
in the apparently monoclonal clinical samples. These 
samples showed a high prevalence (> 60%) of mutations 
N51I, C59R and S108N in pfdhfr, known to be asso-
ciated with resistance to pyrimethamine. The S108N 
mutation was the most represented with a prevalence 
of 69%, whereas the mutation 16V/S, associated with 
resistance to cycloguanil [18] and mutation I164L, pre-
viously described for some highly resistant parasites of 
Asian origin [19] and very rare African origins were not 
detected [12]. Five SNPs were genotyped in the pfdhps 
gene at codons 431, 436, 437, 540, 581 and 613, in the 
pfdhps locus; the key mutation at codon K540E was 
not observed, but all other mutations associated with 
modulation of the responses of parasites to sulfadoxine 
were detected at variable frequencies. The mutations in 
codons S436A/F/G and A437G were found in 65 and 83% 
of isolates, respectively, while A581G and A613S muta-
tions were less frequent (0.1–0.25). Four point mutations 
associated with reduced responses to amodiaquine were 
detected in pfmdr1 sequences in codons 86, 184, 1042 
and 1246. The prevalence of a mutation changing codon 
F184Y was 37% whereas the N86Y, N1042D and D1246Y 
mutations were detected at very low prevalence.
Prevalence of pfdhfr, pfdhps and pfmdr1 haplotypes
Haplotypes were reconstituted by including all unambig-
uous data collected at the designated polymorphic posi-
tions in pfdhfr, pfdhps and pfmdr1 sequences (Table  1). 
The wild type genotype N51/C59/S108 (NCS) was iden-
tified in 27% (32/118) of the isolates while the triple 
mutant 51I/59R/108N (IRN) haplotype was detected in 
57% (67/118) of the evaluable clinical samples. The ICS 
and NCN haplotypes (single mutants) and IRS, NRN and 
ICN (double mutants) were less prevalent at 6% (7/118) 
and 11% (12/118), respectively. The pfdhps genotypes 
were defined according to residues found at positions 
437, 540, 581 and 613. A total of 5 distinct genotypes 
were observed. Fourteen % (14/108) of the clinical sam-
ples carried only the wild type A437/K540/A581/A613 
(AKAA) haplotype, single mutant haplotypes GKAA, 
AKAS, and AKGA, a double mutant, GKAS, and a triple 
mutant GAGS (triple mutant) represent 66% (71/108), 
13.% (14/108) and 8% (9/108) of the clinical samples 
tested, respectively. Single and doubly mutated genotypes 
predominate in Niger and represent 78% of the clinical 
samples.
The pfmdr1 haplotypes were defined by identifying the 
residues at polymorphic codons 86, 184, 1042 and 1246. 
The wild-type sequence NFND was the most prevalent, 
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52% (63/121). Haplotypes carrying a single (YFND, 
NYND, NFDD, NFNY) or a double mutation (YYDD, 
NYDD, NYNY, NFDY and YFNY) were found in 40% 
(48/121) and 8% (10/121) of the clinical samples. No 
pfmdr1 genotypes harbouring more than two individual 
mutated codons were detected.
Multilocus pfdhfr/pfdhps and pfdhfr/pfdhps/pfmdr1 
genotypes
Thirty-six clinical samples had full sequence information 
for all three loci. Overall, these parasites carried a wide 
variety of mutations associated with resistance to SP and 
AQ; there was no isolate that was fully wild type at either 
pfdhfr/pfdhps or pfdhfr/pfdhps/pfmdr. With respect to 
genotypes associated with SP resistance, clinical samples 
that carried 3 mutations in the pfdhfr sequences and the 
single 437G in pfdhps (IRN  + GKAA) constituted 26% 
(9/36)—of the clinical samples, but the quintuple mutant 
(IRN  + GEAA) most commonly associated with clini-
cal failure of SP treatment was not observed. However, 
four clinical samples (0.11) did carry a different quin-
tuple mutant (IRN + GKAS) that may be implicated in 
SP resistance [17]. The analysis of multilocus genotypes 
at the pfdhfr/pfdhps/pfmdr loci showed that only two 
clinical samples carried both a triple mutant pfdhfr (IRN) 
and a 184Y allele at the pfmdr1 locus; among these, only 
1 also carried a double mutant pfdhps allele (GKAS) 
(Table 2).
Discussion
Parasites carrying 51I/59R/108N triple-mutant allele 
of pfdhfr and the 437G/540E allele of pfdhps are major 
contributors to SP treatment failure [12, 20–22]. In most 
West African countries, the pfdhps allele with the single 
mutant, 437G are common, but parasites with the triple 
mutant pfdhfr and the key 437G/540E substitutions are 
still rare (see WWARN SP surveyor).
SP intermittent preventive treatment of women in the 
last two trimesters of pregnancy (IPTp) appears to still 
provide some benefit, even in the presence of high lev-
els of this common quintuple genotype [9]. However, 
the WHO recommends surveillance for this genotype, 
and replacement of SP for IPTp when these quintuple 
mutant parasites reach prevalence greater than 50%. 
More recently, in East and Central Africa, parasites with 
a triple mutant pfdhps allele 437G/540E/581G have been 
observed to abrogate the benefits of IPTp with SP in 
some areas of East and Central Africa [23, 24].
The IRN triple mutant allele of pfdhfr was present in 
57% of the clinical samples. The triple mutant pfdhfr is 
Table 1 Sequence polymorphisms in pfdhfr, pfdhps and pfmdr1 genes
The number and prevalence of the various haplotypes are indicated. Residues considered as mutated are underlined and in bold
Marker Category Haplotype Number Prevalence
pfdhfr 51,59,108 Wild type NCS 32 0.27
Single mutant ICS 3 0.03
NCN 4 0.03
Double mutant IRS 1 0.01
NRN 3 0.03
ICN 8 0.07
Triple Mutant IRN 67 0.57
pfdhps 437,540, 581, 613 Wild type AKAA 14 0.14
Single mutant GKAA 66 0.67
AKAS 4 0.04
AKGA 1 0.01
Double mutant GKAS 14 0.14
Triple mutant GKGS 9 0.08
pfmdr1 86,184,1042,1246 Wild type NFND 63 0.52
Single mutant YFND 2 0.02
NYND 38 0.31
Double mutant NFDD 5 0.04
NFNY 3 0.03
YYND 5 0.04
NYDD 1 0.01
NYNY 1 0.01
NFDY 1 0.01
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common in West Africa as reported for neighbouring 
Benin and Burkina Faso and Gabon in Central Africa 
[25–27]. In most of West Africa and likely reflects spread-
ing of parasites that carry the imported pfdhfr Southeast 
Asian allele from East African sources [28–30]. The clini-
cal ramifications of the pfdhfr triple mutant allele may be 
largely counterbalanced by the absence of pfdhfr I164L.
The parasite genotypes of pfdhps in Gabi were more 
complex. The IRN/GAA haplotype, the most frequent 
in Gabi, is a marker of a lineage phylogenetically differ-
ent from those previously identified in Asia and India 
[31]. Twenty-two % (23/108) of the clinical samples car-
ried a mutation both at codon 437G and 613S; moreo-
ver, nine of these clinical samples carry a triple mutant 
allele of pfdhps that also include 581G (GKGS). Only one 
parasite (1/36) observed in Gabi, carried the triple pfd-
hfr with a unique haplotype of pfdhps, 437G/581G. It is 
not clear whether this strong effect of parasites carrying 
the 581G allele in the absence of 540E would be equally 
deleterious.
The mutations in position 613 of the pfdhps gene, and 
the replacement of an isoleucine residue at position 431 
with a valine have seldom been observed outside Niger. 
The I431V mutation was reported the first time in 2007 
in Nigeria for a limited number of clinical samples but, 
in contrast to what was found in Nigeria, the presence of 
the I431V mutation was not associated in Niger with the 
A581G and A613S mutations. Instead, it was associated 
with the S436A and A437G mutations [26, 32].
These reported prevalences of parasites with genotypes 
known to compromise SP efficacy in Gabi are, in any 
case, low and unlikely to generate a significant effect on 
the clinical outcome following preventive treatment with 
SP. The distribution and prevalence of these mutations 
should nevertheless carefully be explored to determine 
their significance in the response of parasites to SP. Most 
important, parasites carrying the I164L mutation of pfd-
hfr and the K540E mutation of pfdhps in addition to the 
“usual” quintuple are even more strongly associated clini-
cal treatment failure and no parasites with this genotype 
were detected in Gabi before the deployment of SMC 
with SP + AQ.
Molecular characterization of the pfcrt and pfmdr1 
markers facilitates prediction of the responses of para-
sites to chloroquine (CQ) and AQ, but also to meflo-
quine and lumefantrine. It has been shown that parasites 
combining both the pfcrt 76T and pfmdr1 86Y muta-
tions and those carrying the pfmdr1 86Y/184Y/ 1246Y 
triple-mutant haplotype are resistant to 4-aminoqui-
nolines and associated with clinical failure with AQ 
treatment [22, 23]. Selection of the pfmdr1 N86/F184/
D1246 haplotype has been reported during treatment 
with artemether–lumefantrine and in infections with 
increased sensitivity to mefloquine and decreased sus-
ceptibility to lumefantrine [23]. Parasites that carry 2 
or more copies of the wild type allele of pfmdr1 are also 
highly resistant to both lumefantrine and mefloquine 
[33]. In Niger, the F184Y mutation was found to be the 
most frequent, with 37% of sequences displaying this 
mutation. The 86Y, 1042D and 1246Y mutations were 
less common, with prevalences of around 0.1. In the 
study region, almost all (88%) the parasites carried the 
NFD or NYD haplotype, reflecting the selection exerted 
by AL, the first line treatment in Niger. Parasites carry-
ing the YYY form were not detected. The pfcrt sequences 
were not determined in this study, but other analyses 
performed in southern Niger during the same period 
showed that the wild-type CVMNK allele (amino acids 
72–76) of the pfcrt gene was present in 85% of clinical 
samples [34]. This is consistent with previous in  vitro 
results, which indicated that the clinical samples from 
Niger respond adequately to other 4-aminoquinolines 
like AQ [30]. The pfmdr1 sequences characterized pre-
dict acceptable susceptibility of infections to AQ. Only 
11% of the clinical samples carried the pfmdr1 86Y muta-
tion and the 86Y/184Y/1246Y triple mutant allele was 
absent. It is also important to recognize that blood-stage 
resistance mechanisms may not prevent anti-folates from 
working to some degree in the liver-stages.
In contrast to other countries, SP treatment has never 
been recommended as a first-line anti-malarial treatment 
in Niger. The artemether–lumefantrine combination was 
introduced in 2005, to replace CQ, whereas the use of AQ 
has remained marginal. The artesunate–amodiaquine 
combination was introduced later on in 2008 to expand 
the options for artemisinin-based combination therapy 
(ACT) available in Niger. The resistance profiles currently 
observed thus reflect the treatment policies implemented 
by the health authorities in Niger over the last 10 years. 
In contrast to this history, the K540E mutation of pfdhps 
is found principally in the regions in which SP was used 
as a first-line treatment to replace CQ before the intro-
duction of ACT. In West African countries in which CQ 
was replaced directly with ACTs, the K540E mutation 
emerged later. Thus, the strength and order of the drug 
pressures exerted on the parasite are likely to constrain 
and structure the parasite populations in a persistent 
manner [10, 12].
It is important to highlight several key limitations 
of our study. First, the sample size is both limited and 
restricted to children presenting at a health centre with 
fever, so the results presented here may not reflect the 
prevalence of these genotypes in the general parasite 
population. However, as children under 5 account for 
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20% of the total population of Niger, the expected benefit 
of SMC could be considerable. Although a high preva-
lence of the triple pfdhfr haplotype was observed, the 
codon 540 of the DHPS gene remained wild type, and SP 
was likely efficacious at least in 2012. Based on the con-
tinued efficacy of SP for prophylaxis in pregnant women, 
it is possible that even in the presence of the “usual” quin-
tuple (IRN/GEA), SP might still retain efficacy for SMC.
Molecular surveys of the prevalence of parasite geno-
types can provide useful information to guide decisions 
on local drug use, particularly for malaria prevention. It 
would be even more useful if the marker prevalence could 
be assumed to apply to other locations, or at least sites 
very close to the site sampled. However, a related study 
of both SP and AQ molecular markers was completed in 
2013 only 15 km away from Gabi, and the prevalence of 
the pfdhps haplotype, 437G/540E was about 20% at the 
beginning of SMC implementation, and rose to about 
50% by the end of the intervention [34]. Although these 
samples were collected 1 year apart, this molecular het-
erogeneity in clinical samples from geographically close 
sites is not uncommon [28, 35].
This spatial heterogeneity is likely to be common, and 
presents a challenge for policy makers who have respon-
sibility for setting drug use policies on a national scale for 
both SMC and IPTp. In any case, regular monitoring of 
anti-malarial drug resistance should remain a key activ-
ity in the sites where SMC and SP IPTp are implemented. 
Given the sometimes large differences between maker 
prevalence, even between nearby sites, determination 
of the molecular marker prevalences in the actual study 
site should be a high priority to monitor anti-malarial 
resistance.
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